| Cell line name |
HCC1419/TDR |
|---|
| Accession |
CVCL_B3ML |
|---|
| Resource Identification Initiative |
To cite this cell line use: HCC1419/TDR (RRID:CVCL_B3ML) |
|---|
| Comments |
Selected for resistance to: DrugBank; DB05773; Trastuzumab emtansine (T-DM1).
Derived from site: In situ; Breast; UBERON=UBERON_0000310. |
|---|
| Sequence variations |
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ala74fs*47 (c.220_226delGCCCCTG); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Heterozygous (from parent cell line).
|
|---|
| Disease |
Breast ductal carcinoma (NCIt: C4017) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_1251 (HCC1419) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
42Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | CLPUB00650
Sabbaghi Mehrjardi M.A.
Uncovering mechanisms of acquired resistance to trastuzumab-emtansine (T-DM1) in HER2 positive breast cancer.
Thesis PhD (2017); Universitat de Barcelona; Barcelona; Spain PubMed=28821558; DOI=10.1158/1078-0432.CCR-17-0696
Sabbaghi Mehrjardi M.A., Gil-Gomez G., Guardia C., Servitja S., Arpi O., Garcia-Alonso S., Menendez S., Arumi-Uria M., Serrano L., Salido M., Muntasell A., Martinez-Garcia M., Zazo S., Chamizo C., Gonzalez-Alonso P., Madoz-Gurpide J., Eroles P., Arribas J., Tusquets I., Lluch A., Pandiella A., Rojo F., Rovira A., Albanell J.
Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer.
Clin. Cancer Res. 23:7006-7019(2017) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_B3ML
|
|---|
| Encyclopedic resources |
Wikidata; Q110432839
|
|---|
| Entry history |
|---|
| Entry creation | 16-Dec-2021 |
|---|
| Last entry update | 19-Dec-2024 |
|---|
| Version number | 6 |
|---|
